ReviewCancer medicine2026
Targeting Autophagy in Ovarian Cancer: The Emerging Role of Ginsenosides.
Review in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOvarian cancer, the third most prevalent gynecological malignancy, is frequently diagnosed at an advanced stage owing to its asymptomatic early progression. Despite the application of conventional therapies, clinical management remains limited by adverse effects and the development of drug resistance. Therefore, the identification of novel therapeutic targets and strategies is urgently needed. Autophagy, a tightly regulated cellular degradation process, plays a dual and context-dependent role in cancer progression and chemoresistance and has emerged as a promising therapeutic target in ovarian cancer. Ginsenosides, the major bioactive constituents of ginseng, exhibit significant anticancer activity in a variety of tumors.
methodsA literature review was conducted to summarize current studies on autophagy regulation in ovarian cancer and the structural characteristics and pharmacological activities of ginsenosides, with particular attention to the molecular mechanisms through which ginsenosides modulate autophagy and their potential therapeutic implications in ovarian cancer.
resultsGinsenosides can modulate autophagy through multiple mechanisms, including activation of the AMPK/mTOR signaling pathway, induction of reactive oxygen species (ROS) accumulation, and regulation of autophagy-related genes (ATGs), ultimately contributing to tumor suppression. Moreover, ginsenosides have demonstrated notable anticancer effects in ovarian cancer, further highlighting their potential clinical value.
conclusionThis review provides a comprehensive overview of current knowledge regarding autophagy regulation in ovarian cancer, summarizes the structural and pharmacological characteristics of ginsenosides, and discusses their emerging role as autophagy-targeting agents, particularly in the treatment of this malignancy. Collectively, these insights offer a new perspective for the development of autophagy-based precision therapies for ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.